OncoMyx Presents at AACR First Data Showing Multi-Armed Myxoma Virotherapy Can Modulate Anti-Tumor Immune Response apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained .
Kronos Bio, Inc.April 10, 2021 GMT
MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition
Pan-cancer anti-tumor activity, including in tumors exposed to prior lines of therapy, seen with intermittent dosing of KB-0742
Initial safety, pharmacokinetic and pharmacodynamic data from the ongoing Phase 1/2 clinical trial for
KB-0742 expected in fourth quarter of 2021
SAN MATEO, Calif. and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today presented preclinical data for KB-0742, a highly selective, orally bioavailable cyclin dependent kinase 9 (CDK9) inhibitor being developed to treat MYC-amplified solid tumors. The data showed that CDK9 inhibition on a
1. Biogen
This company is the first to submit an application to the Food and Drug Administration for a new drug designed to slow the progress of Alzheimer s disease. This ultimately fatal form of dementia affects about one in nine Americans over the age of 65, but there still aren t any drugs to prevent the disease from worsening.
Image source: Getty Images.
We ll probably find out if the FDA s going to stamp Biogen s golden ticket on or before June 6, the latest proposed action date for aducanumab s long-awaited approval decision. The FDA has already rescheduled the action date for this controversial approval decision twice.
email article
Adding the PI3K inhibitor copanlisib (Aliqopa) to rituximab reduced the risk of disease progression or death for patients with relapsed indolent non-Hodgkin s lymphoma (NHL), including those unfit for chemotherapy, a phase III trial called CHRONOS-3 showed.
Among more than 450 patients receiving rituximab, the median progression-free survival (PFS) reached 21.5 months with copanlisib, as compared to 13.8 months for those assigned placebo (HR 0.52, 95% CI 0.39-0.69,
P
Synlogic Presents Data from SYNB1891 Phase 1 Trial at American Association for Cancer Research (AACR) Annual Meeting
- Data demonstrates activation of STING pathway in patients -
- Combination arm of Phase 1 study of SYNB1891 ongoing -
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data on SYNB1891 for the treatment of solid tumors and lymphoma during the American Association for Cancer Research (AACR) annual meeting, April 10-15, 2021.
SYNB1891 is an investigational drug being evaluated in an ongoing Phase 1 clinical trial for the treatment of solid tumors and lymphoma. SYNB1891 is composed of an engineered Synthetic Biotic strain of E. coli Nissle that produces cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. This mechanism can play a